BioSense

Origin AI Appoints Joseph Gwin as Chief Innovation Officer

Retrieved on: 
Thursday, May 4, 2023
WiFi Sensing, BioSense, Academy of National Defense Science, University, Original Ai, Intelligence, Wi-Fi, Research, Mechanical, Traction, Growth, Safety, Data science, Management

ROCKVILLE, Md., May 4, 2023 /PRNewswire/ -- Origin AI, a pioneer of WiFi Sensing and the solution provider revolutionizing what WiFi can do, today announced the appointment of its new executive role, chief innovation officer.  

Key Points: 
  • ROCKVILLE, Md., May 4, 2023 /PRNewswire/ -- Origin AI , a pioneer of WiFi Sensing and the solution provider revolutionizing what WiFi can do, today announced the appointment of its new executive role, chief innovation officer.
  • Joining Origin from Best Buy Health, Joseph Gwin, Ph.D., served as the head of product research and development, focusing on technology innovation and delivery for the company and overseeing its research and development, data science and product engineering teams.
  • "We are thrilled to have filled the chief innovation role with such a seasoned leader as Joseph Gwin," said Spencer Maid, chief executive officer of Origin.
  • As Origin's chief innovation officer, Gwin will help the company bring safety, security and intelligence to every home, business, and car in the world.

Readout Health Biosense device to be tested in JDRF-funded clinical trial in people with Type 1 Diabetes using SGLT inhibitors at Washington University

Retrieved on: 
Tuesday, July 12, 2022
Technology, American Diabetes Association, Clinical trial, Safety, Health, Diabetic ketoacidosis, Multimedia, Ketoacidosis, Volunteering, Washington University School of Medicine, Risk, Patient, Doctor of Philosophy, Review, George Washington University School of Medicine & Health Sciences, MD, Lists of diseases, Insulin, Heart failure, Degenerative disease, Ketone, Chronic kidney disease, T2D, Kidney disease, SGLT, FDA, Ketosis, Person, Exercise, Obesity, DKA, Efficiency, Industry, JDRF, Medical device, Pharmaceutical industry, T1D, Research, BioSense, St. Louis

ST. LOUIS, July 12, 2022 /PRNewswire/ -- Readout Health, a medical digital health startup, announces a sponsored research agreement with Washington University School of Medicine in St. Louis that received a $360,000 research grant from JDRF. The two-year grant is aimed at testing the efficacy of the Biosense® handheld breath ketone monitor in persons with type 1 diabetes (T1D) during usual care with insulin and with the addition of a sodium glucose transporter inhibitor (SGLT2i) drug. Janet McGill, MD, a professor at Washington University School of Medicine and the recipient of the American Diabetes Association's 2022 Outstanding Physician Clinician award, will serve as the principal investigator.

Key Points: 
  • $360,000 grant to review safety and accuracy of Biosense device aimed at DKA risk mitigation in patients using SGLTi drug class.
  • ST. LOUIS, July 12, 2022 /PRNewswire/ -- Readout Health, a medical digital health startup, announces a sponsored research agreement with Washington University School of Medicine in St. Louis that received a $360,000 research grant from JDRF.
  • Janet McGill, MD, a professor at Washington University School of Medicine and the recipient of the American Diabetes Association's 2022 Outstanding Physician Clinician award,will serve as the principal investigator.
  • Development of ketone monitoring technologies like Biosense are a critical part of the strategy to enable safe, effective use of SGLT inhibitors in type 1 diabetes."

Former Itamar Medical CEO & President Gilad Glick Joins IceCure Medical as a Strategic Advisor for Global Go-To-Market Operations

Retrieved on: 
Tuesday, July 5, 2022
Annual report, Acquisition, Patient, CEO, Adoption, Company, U.S. Securities and Exchange Commission, TASE, Kidney, Food, Marketing, Private Securities Litigation Reform Act, Technology, Freezing, CE marking, Genta (company), Standard of care, Breast, BioSense, SEC, Risk, NASDAQ, VP, Board, Acceleration, Regulation of tobacco by the U.S. Food and Drug Administration, Pharmaceutical industry, Medical imaging, EU

CAESAREA, Israel, July 5, 2022 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of minimally-invasive cryoablation technology, the ProSense® System, that destroys tumors by freezing as an alternative to surgical tumor removal ("ProSense"), today announced that Gilad Glick will serve as a strategic advisor to the Company, to guide its commercialization strategy up to execution. Mr. Glick will support the acceleration of IceCure's Go-to-Market operations for global adoption of ProSense® with a special focus on the U.S. and EU markets.

Key Points: 
  • Mr. Glick will support the acceleration of IceCure's Go-to-Market operations for global adoption of ProSense with a special focus on the U.S. and EU markets.
  • "Gilad is one of the world's leading medical device commercialization strategists and we look forward to working closely with him.
  • ProSense has tremendous potential across numerous medical indications in global markets, and we believe Gilad's expertise will add significant value to IceCure," stated IceCure CEO Eyal Shamir.
  • Mr. Glick was CEO of Itamar Medical from 2013 through 2022 when Itamar Medical was acquired by ZOLL Medical Corporation for $538 million.

SFIO and NeuroSky sign $15-M partnership to bring biotech wearables to global markets

Retrieved on: 
Tuesday, November 30, 2021
Western Asset Management Company, SOS, Amazon, SFIO, United Arab Emirates, Global Academy, Technology, Retirement, Acquisition, Health, Education, GLOBE, NeuroSky, Silicon, OTC, Aegis Global Academy, Schneider Electric, AIG, Degenerative disease, BioSense, Medical device

NeuroSky is a Silicon Valley-based, private biotech company that specializes in electronic wearables such as watches, wrist bands, and headsets.

Key Points: 
  • NeuroSky is a Silicon Valley-based, private biotech company that specializes in electronic wearables such as watches, wrist bands, and headsets.
  • The agreement grants SFIO exclusive rights to sell NeuroSky products in New Zealand and the United Arab Emirates.
  • SFIO also has non-exclusive distribution rights in Malaysia, Singapore, Thailand, the United States, and other countries yet to be determined.
  • These new products will be manufactured by NeuroSky and will fall under a new white label brand currently being developed by SFIO.

Industry Veteran Ty Miller Joins Attune Medical as National Sales Director

Retrieved on: 
Thursday, October 28, 2021
Surgery, Health, Medical Devices, National Interoperability Field Operations Guide, Paola Lattus, Atrial fibrillation, BioSense, Technology, Knowledge, Esophagus, History, Medicine, Adoption, FDA, Electrophysiology, Johnson & Johnson, Miller, Solution, Temperature, Heart

Attune Medical, a pioneering medical device company with a technology platform based on temperature management using the esophageal space, has added Ty Miller to the management team as National Sales Director.

Key Points: 
  • Attune Medical, a pioneering medical device company with a technology platform based on temperature management using the esophageal space, has added Ty Miller to the management team as National Sales Director.
  • Miller has decades of award-winning commercial sales management experience with successful initiatives in gaining clinical acceptance and adoption of pioneering disruptive medical device technologies and procedures.
  • He joins Attune after nearly 15 years with AtriCure, driving the companys innovative technology platform forward in the electrophysiology and cardiothoracic surgery spaces.
  • Ty brings a wealth of experience to Attune, and we are thrilled to have him join our team, commented Maria Gray, VP Clinical and Field Operations.

inHEART appoints industry veteran Todor Jeliaskov as new CEO to drive commercial growth

Retrieved on: 
Thursday, October 21, 2021
Arrhythmia, BioSense, Technology, Cardiology, Norwest Venture Partners, MBA, Organization, Patient, VC, Leadership, Doctor of Philosophy, VP, CEO, Growth, Cardiac electrophysiology, Siemens Healthineers, ICE, Health, Electrical engineering, CTO, LIRYC, DNA, Management, Medical imaging, Medical device

PESSAC, France, Oct. 21, 2021 /PRNewswire/ -- inHEART , the leader in image guidance for treatment of cardiac arrhythmias, has appointed Todor Jeliaskov as CEO.

Key Points: 
  • PESSAC, France, Oct. 21, 2021 /PRNewswire/ -- inHEART , the leader in image guidance for treatment of cardiac arrhythmias, has appointed Todor Jeliaskov as CEO.
  • Todor Jeliaskov will work closely with co-founder and former CEO Jean-Marc Peyrat, who transitions to the role of CTO at inHEART.
  • "I am thrilled to welcome Todor as our new CEO," said Jean-Marc Peyrat, co-founder of inHEART.
  • Before inHEART, Todor Jeliaskov was CEO of NuVera Medical, acquired by Biosense Webster (Johnson & Johnson) in November 2020.

CDC Awards ICF $31 Million Health Surveillance Contract

Retrieved on: 
Tuesday, October 5, 2021
Policy, Coronavirus, Public sector, Risk, Security (finance), Health, BioSense, Private Securities Litigation Reform Act, NASDAQ, U.S. Securities and Exchange Commission, Multimedia, Centers for Disease Control and Prevention, ICF, CDC, Public health, Consultant, Private sector, COVID-19, View, Zika fever, Maintenance, Organization, Contract, ICFI, Government, Industry, Vaccine

BioSense increases the ability of local, state and national health officials to monitor and respond to the harmful health effects of exposure to disease, addiction and hazardous conditions.

Key Points: 
  • BioSense increases the ability of local, state and national health officials to monitor and respond to the harmful health effects of exposure to disease, addiction and hazardous conditions.
  • ICF will work with CDC's Division of Health Informatics and Surveillance and its partners to improve syndromic surveillance efficacy and coverage, national platform sustainability, partner and community outreach and analytic capabilities.
  • "We have built strong, trusted partnerships with the syndromic surveillance community and public health partners and bring the technical, analytical and public health expertise needed to continue to modernize and optimize this crucial national resource."
  • ICF brings together a broad set of public health, health technology and technical support services to help organizations solve their most complex challenges.

Ocuphire Announces Financial Results for the Second Quarter 2021 and Provides Corporate Update

Retrieved on: 
Thursday, August 12, 2021
SEC, ASCRS, DME, Republic, Company, U.S. Securities and Exchange Commission, Research, Risk, Diabetic retinopathy, Cataract, COVID-19, ARVO, IP, Annual general meeting, Security (finance), FDA, Private Securities Litigation Reform Act, NASDAQ, ATM, Technology, OCUP, Nasdaq, Society, DR, Presbyopia, PCSA, GLOBE, BioSense, LDP, Insurance, NDA, Maintenance, Refractive surgery, MBA, Association, American Society of Cataract and Refractive Surgery, CEO, Review, Light, Pharmaceutical industry, Medical imaging, Cryptocurrency

FARMINGTON HILLS, Mich., Aug. 12, 2021 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders, today announced financial results for the second quarter of 2021 and provided a corporate update.

Key Points: 
  • FARMINGTON HILLS, Mich., Aug. 12, 2021 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders, today announced financial results for the second quarter of 2021 and provided a corporate update.
  • Ocuphire reported positive topline data in March 2021 for MIRA-2, a Phase 3 FDA registration study for treatment of RM.
  • Ocuphire also reported positive top-line data in June 2021 for VEGA-1, a Phase 2 trial for the treatment of presbyopia.
  • Ocuphire undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Breath Biomarker Startup Readout Health Announces Release Of Precisionfast™ For Dietary Fasting Protocols In $3B Fasting Market, First Fasting Clinical Trial

Retrieved on: 
Thursday, July 8, 2021
Metabolism, Ketosis, BioSense

"PrecisionFast is a natural progression from nutritional ketosis with carb restrictive diets to food restrictive protocols and consumer nutritional plans.

Key Points: 
  • "PrecisionFast is a natural progression from nutritional ketosis with carb restrictive diets to food restrictive protocols and consumer nutritional plans.
  • The real value is the combination of both, and the market has been asking for their own data and guidance to remove the guesswork," states Readout Health CEO Jim Howard.
  • Readout also has announced a fasting research collaboration with Charite Universitatsmedizin in Berlin, one of the largest medical research centers in Europe.
  • Biosense is used in clinical research, clinics using ketosis therapy, and consumers in the US, Canada, Hong Kong, and Singapore.

LifeOmic Partners with Readout Health to Integrate Ketosis Monitoring in LIFE Apps

Retrieved on: 
Wednesday, March 18, 2020
Health software, Ketosis, Metabolism, BioSense, Mobile app, Health, Articles, Branches of biology

INDIANAPOLIS, March 18, 2020 /PRNewswire/ -- LifeOmic , the creator of the LIFE mobile apps, announced a partnership with Readout Health today allowing LIFE app users to integrate data from the BIOSENSE () ketone tracking device.

Key Points: 
  • INDIANAPOLIS, March 18, 2020 /PRNewswire/ -- LifeOmic , the creator of the LIFE mobile apps, announced a partnership with Readout Health today allowing LIFE app users to integrate data from the BIOSENSE () ketone tracking device.
  • The LIFE mobile apps utilize the data to help users optimize ketosis for weight loss and metabolic health.
  • "Readout Health allows us to offer new scientific insights to LIFE mobile app users to further improve their health," said Dr. Don Brown, CEO and founder of LifeOmic.
  • "LifeOmic aligns with Readout Health's mission to empower people with personalized data throughout the day tools to drive behavioral change and better health outcomes," said Jim Howard, CEO of Readout Health.